Director Samuel Broder resigns from Sensei Biotherapeutics board; board reduced to eight

Sensei Biotherapeutics, Inc.

Samuel Broder, MD resigned from the Board effective February 5, 2024, not due to any disagreement with the Company.
Dr. Broder will remain as a consultant providing strategic guidance on science, clinical development, and regulatory pathways.
Board reduced from nine to eight directors effective February 6, 2024.
Bill Ringo appointed as Interim Chair of the Nominating and Corporate Governance Committee, effective immediately.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Samuel Broder

Director

SNSE · Sensei Biotherapeutics, Inc.

Effective: 2024-02-05
Filed: February 8, 2024, 6:59 PM ET

On February 5, 2024, after serving for nearly five years on the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”), Samuel Broder, MD notified the Company of his decision to resign from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel Broder resigned as Director at Sensei Biotherapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 5, 2024, after serving for nearly five years on the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”), Samuel Broder, MD notified the Company of his decision to resign from the Board, effective immediately.

View on SEC.gov

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-028396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.